Abstract
Improving the immunogenicity of subunit vaccines, in particular skewing of the immune response towards Th1 type immunity, is crucial for the development of effective vaccines against intracellular infections and for the development of anti-cancer vaccines. Small molecule TLR7/8 agonist hold high potential for this purpose, but suffer from an undesirable pharmacokinetic profile, resulting in systemic inflammatory responses. An effective solution to this problem is covalent ligation to a larger carrier. Here, a degradable nanogel carrier containing a covalently linked imidazoquinoline (IMDQ) TLR7/8 agonist is explored as adjuvant for vaccination against the respiratory syncytial virus (RSV). In vitro and in vivo experiments in mice provide a solid rational base for preferring nanogels over soluble polymers as IMDQ carrier in terms of cellular uptake and lymph node accumulation.
Original language | English (US) |
---|---|
Pages (from-to) | 643-651 |
Number of pages | 9 |
Journal | Biomaterials |
Volume | 178 |
DOIs | |
State | Published - Sep 2018 |
Bibliographical note
Funding Information:B.G.D.G. acknowledges the FWO Flanders and the Flemish Liga Against Cancer for funding. L.N. thanks and the Alexander von Humboldt Foundation for a Feodor Lynen return fellowship and the Fonds der Chemischen Industrie for a Liebig fellowship. LVH is a junior assistant and BS a post-doctoral assistant of the Ghent University department of Biomedical Molecular Biology. S.D. and Y.L. gratefully acknowledge funding from the NIH (NIAID Contract HHSN272201400056C). The authors kindly acknowledge Maria Kokkinopoulou and Ingo Lieberwirth for the transmission electron microscopy images of the nanogels.
Funding Information:
B.G.D.G. acknowledges the FWO Flanders and the Flemish Liga Against Cancer for funding. L.N. thanks and the Alexander von Humboldt Foundation for a Feodor Lynen return fellowship and the Fonds der Chemischen Industrie for a Liebig fellowship. LVH is a junior assistant and BS a post-doctoral assistant of the Ghent University department of Biomedical Molecular Biology. S.D. and Y.L. gratefully acknowledge funding from the NIH (NIAID Contract HHSN272201400056C ). The authors kindly acknowledge Maria Kokkinopoulou and Ingo Lieberwirth for the transmission electron microscopy images of the nanogels.
Publisher Copyright:
© 2018 Elsevier Ltd
Keywords
- Lymph nodes
- Nanogels
- RSV
- TLR agonist
- Vaccine